Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide*. These challenging disorders are genetically complex, often harbouring a range of somatic mutations.
In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases. To get meaningful genetic insights, you need a rapid and streamlined approach for studying all key mutations.
Watch our symposium on demand to learn how rapid next-generation sequencing technology can help provide important molecular insights for haematological malignancy samples.
*Sung H et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians.
Watch Our Symposium
Presenter:
Dr. Grantham is a Clinical Scientist and Head of the Cytogenetics and Molecular Haematology Department at Barts Health NHS Trust in London.
The department operates within the Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) and Marianne and her team offer comprehensive and integrated genomic testing to patients.
Presenter:
Dr. Medani is a consultant Haematopathologist working at the Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) at Barts Health NHS Trust in London.
Hanine and her team participate in integrated reporting of haematology specimens, handling bone marrow and lymph node samples from all hospitals in east and south east London.
